American College of Cardiology

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the SHIFT study's value for cardiologists over various recent heart failure trials.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the factors cardiologists consider in selecting specific beta blockers for heart failure patients.

Data from the PARTNER cohort A trial show transcatheter aortic valve replacement produces similar mortality rates at one year compared with the standard procedure.

Results from the CORONARY trial show no significant difference at one year between patients with CAD who underwent on-pump vs. off-pump CABG.

Results from the ASTRONAUT trial show that adding aliskiren to standard therapy for chronic heart failure does not improve mortality or rehospitalization rates.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.

Study results presented at ACC.13 show that patients with unprotected left main coronary artery disease treated with double kissing crush stenting experienced fewer cases of restenosis and other major adverse events compared to patients who received culotte stenting.

Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.

Results from the PARTNER II trial show improvements in 30-day mortality and stroke rates in patients with aortic stenosis who are not surgical candidates who were treated using a newer version of the Sapien transcatheter aortic valve replacement system.

Landmark study results presented at ACC.13 reveal patients with vascular disease treated with niacin therapy face increased risk of myopathy and other adverse events.

Results of the ARMYDA-9 CAROTID trial indicate that loading with 600 mg clopidogrel and high-dose atorvastatin in carotid stent patients independently result in improved neurological outcomes.

Study results presented at ACC.13, the 62nd Annual Scientific Session & Expo of the American College of Cardiology, reveal that in selected STEMI patients, deferred stenting may reduce no-reflow and thrombotic events compared with immediate stenting.

News and updates about ACC.13, the 2013 Scientific Session of the American College of Cardiology.

How long should a patient take an antiplatelet drug to reduce clotting following a stent procedure?

The H2H initiative includes the use of innovative health technologies such as HIT solutions, home monitoring devices, and telehealth resources.

EHRs address a key barrier to care as cardiologists lack the information and the tools to apply their knowledge to all of their patients all of the time.

Study results show Rheos implantable device is effective at lowering blood pressure in patients with drug-resistant hypertension.

RIVAL study shows radial access for coronary interventions reduces vascular complications.

No significant differences on cardiovascular outcomes were seen in a trial that compared ARBs to CCBs in patients with glucose tolerance and hypertension.

Combination calcium channel blocker and angiotensin II receptor blocker proves most effective in a study of elderly patients with hypertension.

Dr. Joe Kim speaks with Dr. Ethan Anderson about what's being discussed at ACC's 60th Annual Scientific Sessions.

Dr. Joe Kim speaks with Bruce Brandes of Airstrip Technologies about the company's new partnership with General Electric.

Study shows that a long-acting zotarolimus-eluting stent is effective in treating de novo lesions in native coronary arteries.

Study shows that percutaneous treatment of mitral regurgitation using MitraClip is no better than a surgical approach.

Studies comparing CABG and medical therapy in patients with heart failure show that viable myocardium has no effect on mortality.

Physicians from several large health systems share their insights and strategies for improving the quality of cardiac care delivered to patients.

Dr. Joe Kim shares his thoughts about a session during which cardiologists debated about the controversies associated with electrophysiology.

Can pulse pressure predicted white coat effect in treated hypertensive patients?

Dr. Douglas Moodie shares his concerns about what is going to happen with health care under ObamaCare.

Dr. Julie Atay discusses the two main objectives of her poster which evaluated the cost analysis of substituting Dabigatran for Warfarin.